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ABSTRACT
Introduction: Acute bacterial skin and skin
structure infections (ABSSSIs) are among the
most common infections treated in hospitals,
but to date, there has been little information
with regards to the implementation of
Antimicrobial Stewardship Programs (ASPs) for
patients with ABSSSIs. Hence, we aim to
evaluate the impact of ASPs on the following
outcomes in patients with ABSSSIs: duration of
therapy and hospital stay, 14-day reinfection,
infection-related readmissions and mortality.
Methods: A retrospective review of the ASP
database was conducted, focusing on selected
outcomes (as above) among all patients in
whom the institution’s ASP recommended a
change in antibiotic regimen—de-escalation of
the antibiotic based on culture results;
discontinuation of the antibiotic; narrowing of
the empirical coverage; and intravenous-to-oral
(i.v.-to-p.o.) switch between September 2009
and December 2012. Data were expressed as
mean ± standard deviation for continuous
variables, and unpaired Student’s t test was
performed to determine intergroup differences
between mean values. For categorical variables,
data were presented as number and percentage
and analyzed using the v2 test or Fisher’s exact
test, as appropriate.
Results: ASP recommended 407 interventions
with an overall acceptance rate of 66.8%. ASP
interventions significantly reduced median
duration of therapy by 2 [from a median
(interquartile range, IQR) of 8 (6–12) days to 6
(4–9) days] and median length of stay by 5 days
[from median (IQR) of 12 (5–32) days to 7
(3–18) days]. This led to an estimated total cost
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avoidance of USD 0.7 million. There were no
significant differences in the 14-day reinfection,
infection-related readmission and mortality
rates between patients whose physicians
accepted and those who rejected ASP
interventions.
Conclusion: Interventions recommended by
the ASP in Singapore General Hospital were
safe and associated with a significant reduction
in duration of therapy and hospital stay. The
results of our study have affirmed the role of ASP
in optimizing the care of patients with ABSSSI.
Keywords: Acute skin and skin structure
infections; Antimicrobial stewardship program;
Impact; Outcomes
INTRODUCTION
Acute bacterial skin and skin structure
infections (ABSSSIs) are ubiquitous and among
the most common infections treated in
hospitals. They differ in severity, and patients
who present to the hospital with severe
infection or whose infection is progressing
despite empirical antibiotics given in
outpatient settings should be treated more
aggressively [1]. Complicated ABSSSIs represent
the more severe end of the spectrum of all
ABSSSIs and require timely initiation of
appropriate antibiotics. Though many studies
have identified the common pathogens
involved in ABSSSI, the emergence of strains
with resistance to multiple agents has
complicated the choice of empirical therapy
[2]. Undeniably, antibiotic resistance is mainly
driven by overusing antibiotics or by
prescribing them inappropriately.
A study conducted in an academic medical
center in the USA revealed that despite the
gram-positive etiology of most cases of ABSSSIs,
two-thirds of their patients were treated with
broad-spectrum gram-negative antimicrobial
agents and even more received anaerobic
therapy [3]. The same study also showed that
hospitalizations for ABSSSI are now more
common than for community-acquired
pneumonia. In a separate matched cohort
study, it was found that the management of
complicated ABSSSIs in hospitalized patients led
to frequent use of potentially unnecessary
diagnostic studies, broad-spectrum antibiotic
therapy and prolonged treatment courses. This
in turn results in a longer length of hospital
stay, higher hospitalization charges, increased
risk of adverse events from prolonged
antimicrobial therapy and higher mortality
rates. These findings suggest the need for
Antimicrobial Stewardship Programs (ASPs) [4].
ASPs were implemented in various countries
in an attempt to control the phenomenon of
increasing antimicrobial resistance, especially
in developed countries. Studies have shown
that ASPs can effectively reduce antibiotic
utilization, cost of care and even antimicrobial
resistance rates [5]. To date, there has been little
information with regards to the
implementation and achievements of ASP to
patients with ABSSSI. Hence, in this study, we
aim to evaluate the impact of ASP on the
following outcomes in patients with skin and
soft tissue infections: (1) duration of therapy,
(2) length of hospital stay, (3) readmission
within 30 days of discharge, (4) 14-day
reinfection post intervention and (5) mortality
within 30 days of ASP audit.
METHODS
Study Design and Setting
This is a single-center, retrospective study
conducted at Singapore General Hospital
(SGH). SGH is Singapore’s largest acute-tertiary
S16 Infect Dis Ther (2015) 4 (Suppl 1):S15–S25
care hospital, with a capacity of 1579 beds. A
review of the ASP database was conducted, for
interventions made between September 2009
and December 2012. For the purpose of this
study, only the following outcomes were
selected for analysis: duration of therapy,
length of hospital stay, readmissions, 14-day
reinfection and mortality. Patients were
classified into two groups: (1) those whose
primary physicians accepted ASP interventions
(accepted group); (2) those whose primary
physicians rejected ASP interventions (rejected
group). During the study period, the audit was
progressively expanded to include the following
departments: General Surgery (October 2008),
Endocrinology (March 2009), Renal Medicine
(April 2009), Colorectal Surgery (October 2009),
Plastic Surgery (October 2009), Internal
Medicine (March 2010), hospital-wide
carbapenem audit (January 2011) and
Orthopaedic Surgery (December 2012).
Description of Our ASP [5]
The ASP team, consisting of an infectious
diseases (ID) physician, clinical microbiologist
and ID clinical pharmacists, drew up new
antibiotic guidelines for surgical prophylaxis as
well as empirical treatment of common
infections. Evidence for these guidelines was
drawn from published guidelines by the
Infectious Diseases Society of America (IDSA)
and the British Society for Antimicrobial
Chemotherapy (BSAC) and was adapted to
SGH’s microbial susceptibility patterns. These
guidelines were approved by the institution’s
Pharmacy and Therapeutics (P&T) Committee
and endorsed by the Medical Board before they
were uploaded on the institution’s intranet. The
ASP team also drew up an intravenous-to-oral
(i.v.-to-p.o.) conversion algorithm (1) to
facilitate and encourage the appropriate use of
oral formulations and (2) to prevent
unnecessary i.v. antibiotic use to reduce costs.
Please refer to Fig. 1 for our ASP workflow.
Briefly, all patients who received carbapenems,
cefepime, piperacillin/tazobactam or parenteral
ciprofloxacin were identified from the
pharmacy database on a daily basis and were
subjected to the two-stage prospective audit
with immediate and concurrent feedback. For
the first stage of the review, trained ID clinical
pharmacists assessed the appropriateness of
antibiotics prescribed and made therapeutic
recommendations to optimize drug dosing
and also to encourage i.v.-to-p.o. conversions.
At the second stage of the review, the
complicated cases with diagnostic
conundrums were brought up for discussion
with an ID physician. The ASP team will follow
up on the audited patient cases on the 2nd,
4th (giving a 72-h period for bacterial cultures
to be processed) and 7th day (if applicable) of
antibiotic prescription, with recommendations
for discontinuation, change, dose adjustment,
de-escalation of antibiotics or duration of
antibiotic use where appropriate. On day 2 of
the antibiotic prescription, the ASP team will
evaluate the empiric use of audited antibiotics
based on the institution antibiotic guidelines
as well as antibiogram. As bacterial cultures
usually require 48–72 h to be processed by our
microbiology laboratory, the ASP team will do
a second review at day 4, when culture results
are reported. At day 4, if the choice of the
audited antibiotic is marked as ‘appropriate
use’ by the ASP team, the case will then be
followed up with regards to the duration of
therapy. As there is no fixed duration of
therapy recommended for various ABSSSIs,
the ASP team will follow up at days 7, 10 and
14 of therapy to review and assess the wound
and to correlate with patients’ clinical status
before making any intervention. Should the
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patient require prolonged antibiotic therapy
(e.g., in patients with abscesses), the ID
pharmacists in the ASP team will review the
case weekly thereafter. Sometimes, clinical tests
(cultures and/or procalcitonin, etc.) were
recommended by the ASP team to guide the
judicious use of antibiotics. Antibiotics were
considered to be inappropriately prescribed if
one or more of the following criteria were met:
(1) a narrower spectrum antibiotic could be
used based on the culture results; (2) there was
no infection present (i.e., bacterial
colonization or an alternative explanation for
the fever present); (3) hospital antibiotic
guidelines were not followed without valid
reasons; (4) dosage, duration of therapy and/
or empirical treatment choice was suboptimal
according to the available guidelines.
Data Collection and Outcomes
Compliance with or rejection of ASP
recommendations was determined via chart
review 24 and 48 h post recommendation as
part of the clinical workflow. If the
recommendations were adopted after this time
frame, they were still considered to be rejected
for the purposes of this study. In addition, this
study will also aim to estimate the cost avoidance
associated with the selected outcomes—
duration of therapy, length of hospital stay,
readmissions, 14-day reinfection and mortality.
Definitions
For the purpose of this study, only four types of
interventions were evaluated as these
Fig. 1 Schematic diagram of the antimicrobial stewardship program prospective audit with immediate concurrent feedback
workﬂow. ID infectious diseases
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interventions potentially could have a direct
impact on the selected outcomes as listed
above. These interventions include
de-escalation of the antibiotic based on culture
results, discontinuation of the antibiotic,
narrowing of empirical coverage and
i.v.-to-p.o. switch. While the ASP team
occasionally recommends additional
investigations, infection control measures or
ID referral, such interventions in this analysis
were not included as they are less likely to have
a direct impact on the selected outcomes.
Thirty-day readmissions were defined as
admissions within 30 days of the date of
discharge. The length of stay (LOS) is defined
as the duration of hospital stay starting from the
date of the ASP intervention to the date of
patient discharge. Mortality was defined as
patients who died within 30 days from the
date of the ASP audit. Absence or presence of
reinfections was evaluated in patients on day 14
post discontinuation of the audited antibiotic
in culture-directed therapies. The reinfection
must be attributable to the same organism
isolated from the same site of infection, with
the same susceptibility, which was treated by
the preceding course of antibiotic therapy. The
classification of ABSSSI severity is adopted from
Dryden [2] (Table 1).
Ethics
The study protocol was approved by the
Singhealth Centralized Institutional Review
Board (CIRB Ref: 2010/114/E). Informed
consent was not obtained from individual
patients as the operations of ASP constituted
routine clinical practice, and only anonymized
data were analyzed.
Statistical Methods
IBM SPSS Statistics (version 20) was used for all
statistical calculations. Data were expressed as
mean ± standard deviation for continuous
variables, and unpaired Student’s t-test was
performed to determine intergroup differences
between mean values. For the length of hospital
stay post-ASP intervention, data were expressed
as median values with range and compared via
the Mann-Whitney U-test. For categorical
variables, data were presented as the number
and percentage and were analyzed using v2 test
or Fisher’s exact test, as appropriate.
Table 1 Classiﬁcation of ABSSSI severity [2]
Category Clinical features Management
Class 1 ABSSSI but no signs or symptoms of systemic toxicity or
comorbidities
Drainage (if required) and oral antibiotics as
outpatient
Class 2 Either systematically unwell or systematically well but
with comorbidity (e.g., diabetes) that may complicate or
delay resolution
Oral or outpatient intravenous antibiotic therapy,
may require short period of observation in
hospital
Class 3 Toxic and unwell (fever, tachycardia, tachypnea and/or
hypotension)
Likely to require inpatient treatment with
parenteral antibiotics
Class 4 Sepsis syndrome and life-threatening infection (e.g.,
necrotizing fasciitis)
Likely to require admission to ICU, urgent surgical
assessment and treatment with parenteral
antibiotics
ABSSSI acute bacterial skin and skin structure infections, ICU intensive care unit
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RESULTS
Interventions
The ASP team recommended a total of 407
interventions (Table 2), with an average
acceptance rate of 66.8% (272/407), between
September 2009 and December 2012. There
were no statistically significant differences in
terms of age, gender, previous hospitalization
within 3 months and previous antibiotic use
within 3 months between the accepted group
and rejected group, as defined above (Table 3).
The most commonly audited antibiotics were
piperacillin/tazobactam (48.4%), parenteral
ciprofloxacin (22.1%), meropenem (10.8%)
and cefepime (10.0%).
Duration of Therapy
The antibiotic use duration was significantly
shorter by 2 days (P\0.01) in the group of
patients whose physicians accepted ASP
interventions [median (IQR) of 6 (4–9) days]
when compared to the group whose physicians
rejected ASP interventions [median (IQR) of 8
(6–12) days], as shown in Table 4.
Length of Stay
The LOS from the ASP intervention and
discharge from the hospital was significantly
shorter by 5 days (P\0.01) in the accepted
group [median (IQR) of 7 (3–18) days] than in
the rejected group [median (IQR) of 12 (5–32)
days]. According to the local Ministry of Health
hospital bill size data (updated March 2015), the
estimated total cost avoidance from the
reduction in length of hospital stay is USD 0.7
million.
Reinfection
There were 141 patients with positive
microbiological cultures. Of these, 4 (8%) of
the 50 patients in the rejected group had
reinfection within 14 days, while 2 (2.2%) of
the 91 patients in the accepted group had
reinfection within 14 days. However, the
difference in the 14-day reinfection rates
between the accepted and rejected group was
not statistically significant (P = 0.10).
One patient in the accepted group had a
right foot abscess where pan-sensitive
Pseudomonas aeruginosa was isolated
intraoperatively. The ASP team had intervened
to use oral ciprofloxacin when the wound was
improving, and the primary team accepted the
intervention. However, in view of the poor
glycemic control and slow wound healing, the
patient subsequently underwent multiple
debridements for source control, and again,
intraoperative culture grew pan-sensitive P.
aeruginosa. The second patient, who had
colorectal carcinoma of the sigmoid,
complicated with perianal fistula, was
admitted for a right buttock abscess (secondary
to tumor fistulation). The patient underwent
surgical drainage of the abscess and
subsequently a second round of wound
debridement. The patient was initiated on i.v.
cefepime based on intraoperative culture that
grew pan-sensitive P. aeruginosa. After 10 days of
i.v. cefepime, the patient had improved
Table 2 Selected interventions analyzed in this study
Intervention N Accepted
[n (%)]
De-escalation based on culture results 57 39 (68.4)
Discontinue antibiotic 173 118 (68.2)
Intravenous-to-oral switch 118 76 (64.4)
Narrowing of empirical coverage 59 39 (66.1)
Total 407 272 (66.8)
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clinically, and the surgical wound was healing
well. The ASP team had intervened to
discontinue i.v. cefepime. The intervention
was accepted, and patient was subsequently
discharged well 4 days thereafter. However, at
5 days post discharge, the patient was
readmitted for fever, and her perianal wound
was noted to be foul smelling. Wound swab
culture grew the same pan-sensitive P.
aeruginosa, and the patient was re-initiated on
another course of i.v. cefepime.
Readmissions
Of the 383 surviving patients, 24 out of 254
patients (9.45%) in the accepted group was
readmitted within 30 days from discharge, with
a clinical diagnosis of ABSSSI, while 9 out of 129
patients (6.98%) in the rejected group was
readmitted for ABSSSI. The difference in
readmission rates between the two groups was
not statistically significant (P = 0.42).
Mortality
Of the 272 patients in the
intervention-accepted group, 254 (93.4%)
survived beyond 30 days after discharge, while
129 (95.6%) out of 135 in the
intervention-rejected group survived beyond
30 days after discharge. For mortality due to
ABSSSI, there were 4 (1.47%) patients in the
accepted group and 3 (2.22%) in the rejected
group. There was no statistical difference in
terms of 30-day all-cause mortality (P = 0.38) as
well as 30-day mortality due to ABSSSI
(P = 0.69) between the two groups.
Table 3 Patient demographics
Demographics Accepted group (N5 272) Rejected group (N5 135) P value
Mean age (years) 63.7 62.2 0.35
Male gender 152 (55.9) 79 (58.5) 0.61
Previous hospitalization within 3 months 140 (51.5) 66 (48.9) 0.62
Previous antibiotic use within 3 months 186 (68.4) 95 (70.4) 0.68
Charlson comorbidity score
1–2 58 34
3–4 66 33 0.67
C5 148 68
Median (IQR) 5 (3–7) 5 (2–6)
Classiﬁcation category for ABSSSI severity
1 0
2 119 52 0.927
3 119 60
4 34 23
Median (IQR) 3 (2, 3) 3 (2, 3)
Data are n (%) unless otherwise stated
ABSSSI acute bacterial skin and skin structure infections, IQR interquartile range
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DISCUSSION
As evident by the results of our study, ASP
interventions are important to improve the
quality of prescribing and to guide physicians
on the appropriate duration of antibiotics
without compromising on patient’s safety.
Moreover, in our institution, ASP reviews
commence on the 2nd day of antibiotic
prescription, allowing for timely feedback and
intervention. Prospective audit as well as
feedback intervention is one of the two core
ASP strategies recommended by the IDSA [6]
that has been shown to be effective.
While guidelines have suggested an average
of 5–10-day duration for cellulitis [1] and a
longer duration if there are abscesses, more
often than not, physicians extend the duration
of therapy beyond recommendations in view of
poor resolution of the infection. We have
shown that our ASP interventions were
effective in reducing the median duration of
antibiotic therapy by 2 days (P\0.01), as well as
reducing the median LOS by 5 days (P\0.01),
without compromising the safety of our
patients. It was also suggested that limiting
the treatment duration seemed to be the most
effective method, where antibiotic
administration can be modified, to reduce
antibiotic resistance as well as the other
drug-related deleterious effects such as ADRs [7].
Concomitant with a reduction in the
duration of antibiotic therapy, ASP
interventions have also effectively reduced the
median LOS by 5 days. This is most likely
attributed to cases where physicians accepted
interventions to discontinue the antibiotic and/
or to switch to oral antibiotics. The prolonged
LOS for patients in the rejected group may be
explained by the need to complete a prolonged
course of parenteral antibiotic therapy, contrary
to ASP recommendations. Early discharge from
the hospital will result in a reduction in
treatment costs and relieve bed crunch
problems, but, more importantly, substantially
reduce patients’ risk of acquiring nosocomial
Table 4 Impact of ASP interventions on the selected outcomes in patients with ABSSSI
Outcomes Accepted group (N5 272) Rejected group (N5 135) P value
Duration of therapy (days), median (IQR) 6 (4–9) 8 (6–12) \0.01*
Length of stay (days), median (IQR) 7 (3–18) 12 (5–32) \0.01*
30-day all-cause mortality 18 (6.60) 6 (4.44) 0.38
30-day mortality due to ABSSSI 4 (1.47) 3 (2.22) 0.69
(N5 254) (N5 129)
30-day readmission due to ABSSSI 24 (9.45) 9 (6.98) 0.42
(N5 91) (N5 50)
14-day reinfection 0.10
Reinfection absent 89 (97.8) 46 (92)
Reinfection present 2 (2.2) 4 (8)
Data are n (%) unless otherwise stated
ABSSSI acute bacterial skin and skin structure infection, ASP antimicrobial stewardship program, IQR interquartile range
* Statistically signiﬁcant (P\0.05)
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infections. Of note, extended duration of
antibiotic therapy and a longer duration of
hospitalization were associated with a
substantially increased risk of Clostridium
difficile-associated diarrhea, accounting for
20–30% of cases of antibiotic-associated
diarrhea [8]. C. difficile infection is regarded as
an immediate public health threat that requires
urgent and aggressive action [9].
One of the more common interventions
made by ASP was to encourage physicians to
switch to oral therapy, which entails benefits to
both the patient and healthcare system. First, it
reduces the cost of treatment for the patients as
most parenteral antibiotics are more expensive
than oral formulations, and there are additional
costs associated with preparation and
administration of parenteral formulations.
More importantly, it reduces healthcare costs
by reducing the incidence of catheter-related
infections and allowing for shorter hospital
stays when patients are discharged with oral
antibiotics to complete therapy.
While it may be argued that the patients
whose physicians rejected ASP interventions
were likely more ill and hence reluctant to
switch to an antibiotic of a narrower spectrum
or to switch to oral antibiotics, we found no
significant differences in the baseline
characteristics of patients in the two groups.
Of the 33.2% of cases where ASP interventions
were rejected, approximately half of them were
rejected because of the physician’s personal
preference, with no clear reasons indicated.
Some possible reasons could be that physicians
are not inclined to accept interventions when
they deviate from their clinical judgment or
they may have the misconception that ASP is
driven with the sole purpose to discontinue the
use of antibiotics. Contrary to this, ASP is in
place to ensure the judicious use of antibiotics
and optimize clinical outcomes while
minimizing unintended consequences of
antimicrobial use rather than merely
decreasing antibiotic expenditure [10].
Although not statistically significant, the
14-day reinfection rates were lower in the
accepted group, and this could be a result of
an appropriate choice, with adequate doses and
duration of therapy as recommended by the
ASP, thereby leading to better patient outcomes.
The 30-day readmission rates due to ABSSSIs
were slightly higher in the accepted group
(9.45%) compared to the rejected group
(6.98%), but this difference was not
statistically significant (P = 0.42). The majority
of these patients had conditions that impair
wound healing, such as poorly controlled
diabetes mellitus and peripheral vascular
diseases, and this in turn explained the
recurrent admissions because of ABSSSIs. The
30-day mortality rates for ABSSSIs were
comparable between the two groups (1.47% in
the accepted group, 2.22% in the rejected
group), and this difference was not statistically
significant (P = 0.69). All seven patients, who
died because of ABSSSIs had ‘source control’
issues where surgical interventions such as
amputation were deemed necessary by
physicians in a bid to control the infection.
Two of these patients had high cardiac risk for
surgeries and thus were contraindicated for the
needed surgical interventions required to
control the infections. The remaining five
patients had refused further surgical
interventions and opted for conservative
management with antibiotics and wound
dressings. The ASP team had intervened to
discontinue antibiotics in these seven patients
as they had received prolonged courses of
antibiotics but failed to improve clinically
because of the lack of ‘source control.’
Extending the duration of antibiotics in this
group of patients will not benefit them because
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of medical futility. Instead, it puts patients at a
higher risk of side effects of the antibiotics, as
well as increased risk of C. difficile-associated
diarrhea, as mentioned above.
Of note, our study revealed that many
patients were treated with antibiotics based
on wound/skin swab cultures. While swab
cultures are easily sampled, they are
controversial, especially when obtained from
chronic wounds. The culture may be obtained
from an uninfected wound and lead to
unnecessary antibiotic therapy [11]. The ASP
team in our institution had actively intervened
to educate the primary team about stopping
antibiotics for positive swab cultures from
patients with no clinical infective symptoms,
and positive swab cultures should not be used
to determine whether the wound is acutely
infected. Rather, swab cultures may be used to
identify potential pathogens in a wound judged
to be infected based on clinical criteria in
circumstances where tissue biopsy is not
possible. Future studies may be conducted to
compare patient outcomes where they are
initiated on antibiotic therapies based on
tissue biopsy compared to those who are
treated based on swab cultures.
With a relatively large sample size and
involvement of various specialties, the results
of our study can be applied to a variety of
healthcare settings worldwide. However, the
retrospective nature of our study limits the
amount of information we have with regards to
differences in the severity of diseases and/or
presence of comorbidities that could potentially
affect outcomes. Nevertheless, with similar
baseline demographics between the two
groups, the possibility of such differences
affecting the outcomes is low.
CONCLUSIONS
Interventions recommended by the ASP in SGH
were safe and were associated with a significant
reduction in the duration of antibiotic therapy
as well as a reduction in the length of hospital
stay. Although ABSSSIs are prevalent, little has
been done to improve the quality of prescribing
antibiotics for its management. The results of
our study have affirmed the role of ASP in
optimizing the care of patients with ABSSSIs.
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